An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies

被引:15
|
作者
Premaud, Aurelie [1 ,2 ]
Filloux, Matthieu [3 ,4 ]
Gatault, Philippe [5 ]
Thierry, Antoine [6 ]
Buchler, Matthias [5 ]
Munteanu, Eliza [7 ]
Marquet, Pierre [1 ,2 ,8 ]
Essig, Marie [1 ,2 ,7 ]
Rousseau, Annick [1 ,2 ]
机构
[1] INSERM, U850, Limoges, France
[2] Univ Limoges, UMR S850, Limoges, France
[3] CHU Limoges, Serv Immunol & Immunogenet, Limoges, France
[4] CNRS, CRIBL, UMR 7276, Limoges, France
[5] CHU Tours, Serv Nephrol & Immunol Clin, Tours, France
[6] CHU Poitiers, Serv Nephrol Hemodialyse Transplantat Renal, Poitiers, France
[7] CHU Limoges, Serv Nephrol, Dialyse Transplantat, Limoges, France
[8] CHU Limoges, Serv Pharmacol Toxicol & Pharmacovigilance, Limoges, France
来源
PLOS ONE | 2017年 / 12卷 / 07期
关键词
RENAL-TRANSPLANTATION; SERUM CREATININE; ALLOGRAFT LOSS; FAILURE; REJECTION; OUTCOMES; FORESTS; SYSTEM; COHORT; TIME;
D O I
10.1371/journal.pone.0180236
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most predictive models and scores of graft survival in renal transplantation include factors known before transplant or at the end of the first year. They cannot be updated thereafter, even in patients developing donor-specific anti-HLA antibodies and acute rejection. We developed a conditional and adjustable score for prediction of graft failure (AdGFS) up to 10 years post-transplantation in 664 kidney transplant patients. AdGFS was externally validated and calibrated in 896 kidney transplant patients. The final model included five baseline factors (pretransplant non donor-specific anti-HLA antibodies, donor age, serum creatinine measured at 1 year, longitudinal serum creatinine clusters during the first year, proteinuria measured at 1 year), and two predictors updated over time (de novo donor-specific anti-HLA antibodies and first acute rejection). AdGFS was able to stratify patients into four riskgroups, at different post-transplantation times. It showed good discrimination (time-dependent ROC curve at ten years: 0.83 (CI95% 0.76-0.89).
引用
收藏
页数:16
相关论文
共 50 条
  • [31] De Novo donor-specific anti-HLA antibody risk stratification in kidney transplantation using a combination of B cell and T cell molecular mismatch assessment
    Chou-Wu, Elaine
    Niemann, Matthias
    Youngs, Danny
    Gimferrer, Idoia
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [32] Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience
    Jarmi, Tambi
    Abdelmoneim, Yousif
    Li, Zhuo
    Jebrini, Abdullah
    Elrefaei, Mohamed
    TRANSPLANT IMMUNOLOGY, 2023, 77
  • [33] Pretransplant Immunologic Risk Assessment of Kidney Transplant Recipients With Donor-Specific Anti-Human Leukocyte Antigen Antibodies
    Marfo, Kwaku
    Ajaimy, Maria
    Colovai, Adriana
    Kayler, Liise
    Greenstein, Stuart
    Lubetzky, Michelle
    Gupta, Anjali
    Kamal, Layla
    de Boccardo, Graciela
    Masiakos, Peter
    Kinkhabwala, Milan
    Akalin, Enver
    TRANSPLANTATION, 2014, 98 (10) : 1082 - 1088
  • [34] Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies
    de Kort, H.
    Willicombe, M.
    Brookes, P.
    Dominy, K. M.
    Santos-Nunez, E.
    Galliford, J. W.
    Chan, K.
    Taube, D.
    McLean, A. G.
    Cook, H. T.
    Roufosse, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (02) : 485 - 492
  • [35] Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies
    Senev, Aleksandar
    Van Loon, Elisabet
    Lerut, Evelyne
    Callemeyn, Jasper
    Coemans, Maarten
    Van Sandt, Vicky
    Kuypers, Dirk
    Emonds, Marie-Paule
    Naesens, Maarten
    KIDNEY INTERNATIONAL, 2021, 100 (02) : 401 - 414
  • [36] Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific Antibodies Are Due to Acute Rejection Episodes
    Cooper, James E.
    Gralla, Jane
    Cagle, Linda
    Goldberg, Ryan
    Chan, Laurence
    Wiseman, Alexander C.
    TRANSPLANTATION, 2011, 91 (10) : 1103 - 1109
  • [37] Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies
    Callemeyn, Jasper
    Lerut, Evelyne
    de Loor, Henriette
    Arijs, Ingrid
    Thaunat, Olivier
    Koenig, Alice
    Meas-Yedid, Vannary
    Olivo-Marin, Jean-Christophe
    Halloran, Philip
    Chang, Jessica
    Thorrez, Lieven
    Kuypers, Dirk
    Sprangers, Ben
    Van Lommel, Leentje
    Schuit, Frans
    Essig, Marie
    Gwinner, Wilfried
    Anglicheau, Dany
    Marquet, Pierre
    Naesens, Maarten
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (09): : 2168 - 2183
  • [38] The utility of comprehensive assessment of donor specific anti-HLA antibodies in the clinical management of pediatric kidney transplant recipients
    Gloor, James M.
    PEDIATRIC TRANSPLANTATION, 2011, 15 (06) : 557 - 563
  • [39] De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
    Moayedi, Yasbanoo
    Fan, Chun-Po S.
    Tinckam, Kathryn J.
    Ross, Heather J.
    McCaughan, Jennifer A.
    CLINICAL TRANSPLANTATION, 2018, 32 (11)
  • [40] Impact of the immunotherapy induction on allograft outcome and survival in kidney transplant patients with donor-specific antibodies to HLA-DQB1
    Dutra, Rodrigo S.
    Fabreti-Oliveira, Raquel A.
    Lasmar, Marcus F.
    Araujo, Stanley A.
    Nascimento, Evaldo
    TRANSPLANT IMMUNOLOGY, 2021, 66